NASDAQ:JAZZJazz Pharmaceuticals Stock Price, Forecast & News

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JAZZ shares have increased by 9.1% and is now trading at $117.87. View which stocks have been most impacted by Coronavirus.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jazz Pharmaceuticals.

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Jazz Pharmaceuticals.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.45 EPS for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.24. The specialty pharmaceutical company earned $534.73 million during the quarter, compared to the consensus estimate of $544.55 million. Jazz Pharmaceuticals had a net margin of 12.81% and a return on equity of 21.66%. Jazz Pharmaceuticals's revenue was up 5.2% on a year-over-year basis. During the same period last year, the company posted $3.67 EPS. View Jazz Pharmaceuticals' earnings history.

Jazz Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share (EPS) guidance of 11.25-12.50 for the period, compared to the Thomson Reuters consensus estimate of $12.31. The company issued revenue guidance of $2.12-2.26 billion, compared to the consensus revenue estimate of $2.3 billion.

19 Wall Street analysts have issued twelve-month target prices for Jazz Pharmaceuticals' shares. Their forecasts range from $109.00 to $200.00. On average, they expect Jazz Pharmaceuticals' share price to reach $156.72 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals.

Media headlines about JAZZ stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Jazz Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutJazz Pharmaceuticals.

Jazz Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,790,000 shares, a decline of 5.4% from the April 30th total of 2,950,000 shares. Based on an average daily trading volume, of 693,300 shares, the short-interest ratio is currently 4.0 days. Approximately 5.2% of the shares of the company are sold short. View Jazz Pharmaceuticals' Current Options Chain.

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Visa (V), Bank of America (BAC) and Biogen (BIIB).

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.15%), AQR Capital Management LLC (4.25%), JPMorgan Chase & Co. (3.19%), Nuveen Asset Management LLC (2.96%), State Street Corp (2.72%) and Janus Henderson Group PLC (1.49%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View institutional ownership trends for Jazz Pharmaceuticals.

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., Assenagon Asset Management S.A., JPMorgan Chase & Co., Nuveen Asset Management LLC, KBC Group NV, Wellington Management Group LLP, and AJO LP. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, and Paul Treacy. View insider buying and selling activity for Jazz Pharmaceuticals.

JAZZ stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Sarissa Capital Management LP, APG Asset Management N.V., Janus Henderson Group PLC, PNC Financial Services Group Inc., First Trust Advisors LP, Robeco Institutional Asset Management B.V., and Systematic Financial Management LP. View insider buying and selling activity for Jazz Pharmaceuticals.

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of JAZZ stock can currently be purchased for approximately $117.87.

Jazz Pharmaceuticals has a market capitalization of $6.52 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe.

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]